Akari Therapeutics Plc Filing Effectiveness Notice

Ticker: AKTX · Form: EFFECT · Filed: Apr 16, 2026 · CIK: 0001541157

Sentiment: neutral

Topics: filing-effectiveness, registration-statement, regulatory

TL;DR

Akari Therapeutics Plc filing is now effective as of 4/16/2026. Get ready.

AI Summary

Akari Therapeutics Plc filed an EFFECT form, indicating the effectiveness of a registration statement, on April 16, 2026. The filing relates to Act 33 and has the SEC Accession Number 9999999995-26-001192. The company's mailing and business address is 401 East Jackson Street, Suite 3300, Tampa, FL 33602.

Why It Matters

This filing signifies that a registration statement for Akari Therapeutics Plc has become effective, which is a crucial step for certain securities offerings or transactions.

Risk Assessment

Risk Level: low — This is a procedural filing indicating the effectiveness of a registration statement, not a direct financial event.

Key Numbers

Key Players & Entities

FAQ

What type of filing is this?

This is an EFFECT filing, which signifies the Notice of Effectiveness for a registration statement.

When did this filing become effective?

The filing became effective on April 15, 2026, and was accepted on April 16, 2026.

What is the SEC Accession Number for this filing?

The SEC Accession Number is 9999999995-26-001192.

What is the CIK number for Akari Therapeutics Plc?

The CIK number for Akari Therapeutics Plc is 0001541157.

What is the business address of Akari Therapeutics Plc?

The business address is 401 East Jackson Street, Suite 3300, Tampa, FL 33602.

Filing Details

This Form EFFECT (Form EFFECT) was filed with the SEC on April 16, 2026 regarding Akari Therapeutics Plc (AKTX).

View full filing on EDGAR

View Full Filing

View this EFFECT filing on SEC EDGAR

View on Read The Filing